Last updated: February 20, 2026
What is NDC 82580-0020?
NDC 82580-0020 refers to a specific drug product listed in the National Drug Code database. It is identified as Voretigene Neparvovec-rzyl (Luxturna), a gene therapy approved by the FDA in December 2017 for treating hereditary retinal dystrophy caused by biallelic RPE65 mutations.
Market Landscape Overview
Market Size and Demand
The gene therapy market for inherited retinal diseases (IRDs) is limited by:
- Prevalence: Estimated at approximately 1,000-1,500 patients in the U.S. with RPE65 mutations (NORD, 2022).
- Diagnosis rates: Only a subset receives genetic testing, potentially underestimating actual therapeutic candidates.
- Treatment need and approval: Luxturna gained approval as the first FDA-approved gene therapy for a retinal disease.
Estimated Sales Data
- Initial Launch (2018): Estimated at $175 million in the U.S.
- Growth trajectory: Increasing due to expanding genetic testing, higher diagnosis rates, and awareness.
- Global expansion: Limited by regulatory approvals, with ongoing discussions for European and other markets.
Market Competitors and Pipeline
- Current: No direct competition as Luxturna remains the first approved gene therapy for IRD.
- Future pipeline: Several gene therapies under development for retinal diseases, but none with regulatory approval yet.
Regulatory and Reimbursement Factors
- Pricing: Set at approximately $850,000 per treatment in the U.S.
- Reimbursement landscape: Centers for Medicare & Medicaid Services (CMS), private insurers, and pharmacy benefit managers (PBMs) decide coverage.
- Pricing challenges: High upfront cost, limited patient population, and reimbursement models focused on outcomes.
Price Projections and Analysis
Current Price Point
Future Price Trends
- Potential decrease: As manufacturing scales, costs may decline, but complex logistics and personalized therapy nature limit significant reductions.
- Pricing pressure: Payers may negotiate discounts or implement outcomes-based reimbursement models.
- Premium valuation: The gene therapy's curative potential justifies premium pricing in the short term.
Price Sensitivity Factors
- Market expansion: Broader indications, such as other IRDs, could dilute per-treatment costs.
- Cost-effectiveness: Comparative studies between lifelong management and a one-time gene therapy influence payer decisions.
- Global markets: Price adjustments for different regions, considering local economies and healthcare systems.
Estimated Price Trajectory (Next 5 Years)
| Year |
Estimated Price Range |
Rationale |
| 2023 |
$800,000 – $900,000 |
Stabilization at current price due to manufacturing, logistics, and market valuation. |
| 2024 |
$760,000 – $850,000 |
Slight decline expected with scaling of manufacturing and increased competition. |
| 2025 |
$700,000 – $800,000 |
Possible further reduction driven by reimbursement negotiations and expanded use. |
Key Market Drivers and Risks
Drivers
- Increasing recognition of genetic testing.
- Growing approval for broader indications.
- Payer acceptance of high-cost, one-time treatments.
Risks
- High manufacturing costs limiting price reductions.
- Reimbursement obstacles slowing uptake.
- Competition from emerging therapies or lower-priced generics.
Key Takeaways
- NDC 82580-0020 (Luxturna) has a current market size in the U.S. of approximately $175 million annually.
- The treatment is priced at around $850,000 per dose, with limited price variation expected short-term.
- Long-term price declines are constrained by manufacturing costs and the personalized nature of gene therapy.
- Market growth depends on increased awareness, diagnosis, and regulatory approvals in new markets.
- Competition remains limited but develops as pipeline candidates progress toward approval.
FAQs
Q1: Will gene therapies for hereditary retinal dystrophies significantly reduce prices?
A1: Likely only modestly. Manufacturing complexities and personalized treatments restrict large price reductions in the near term.
Q2: Can expanded indications increase the market size for NDC 82580-0020?
A2: Yes. Successful approvals for additional retinal conditions could notably increase patient eligibility.
Q3: How does reimbursement affect the pricing of Luxturna?
A3: Reimbursement negotiations influence the effective price clients and systems pay, potentially leading to discounts or outcomes-based deals.
Q4: Are there upcoming competitors to Luxturna?
A4: Several gene therapies targeting retinal diseases are in clinical trials, but none have received approval as of 2023.
Q5: What are the main barriers to expanding the use of gene therapies like NDC 82580-0020?
A5: Cost, infrastructure for delivery, long-term efficacy data, and payer acceptance.
References
[1] National Organization for Rare Disorders (NORD). (2022). Hereditary retinal dystrophy facts.
[2] FDA. (2017). FDA approves first gene therapy for inherited disease.
[3] EvaluatePharma. (2022). Gene therapy market size and forecasts.
